Evidence map›Paper›PMID 34595203›Full record

ArticleFrontiers in nutrition2021

Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.

Zhangya He, Xiaomin Li, Hexiang Yang, Pei Wu, Shanshan Wang, Dan Cao, Xiaoxiao Guo, Zhangrui Xu, Jiayi Gao, Wanyu Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Immunonutrition: Another Player on the MASLD Field.International journal of molecular sciences · 2025
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Current strategies for nonalcoholic fatty liver disease treatment (Review).International journal of molecular medicine · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zhangya HeDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Xiaomin LiDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Hexiang YangDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Pei WuDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Shanshan WangDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Dan CaoDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Xiaoxiao GuoDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Zhangrui XuDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Jiayi GaoDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Wanyu ZhangDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Xiaoqin LuoDepartment of Nutrition and Food Safety of School of Public Health, Xi'an Jiaotong University, Xi'an, China.
Xi'an Jiaotong University · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is now recognized as the most prevalent hepatic disorder worldwide, and an unhealthy lifestyle is the leading risk factor for its occurrence. Vitamin C (VC) has been suggested to protect NAFLD, whereas evidence from randomized controlled trials (RCTs) is sparse. In this study, we aimed to investigate the potential benefits of VC supplementation daily on liver health and associated parameters in patients with NAFLD. In this double-blind, RCT, 84 patients with NAFLD, aged 18-60 years old, were assigned to 12 weeks of oral treatment with either low (250 mg/day,

Indexed as

adiponectinglucose metabolismmicrobiotaNAFLDvitamin C

Identifiers

PMID34595203
PMCPMC8478121
OpenAlexW3201198057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.